News
Looking for a biopharma job in New Jersey? Check out the BioSpace list of 11 companies hiring life sciences professionals like you.
FEATURED STORIES
From Eli Lilly’s David Ricks to Pfizer’s Albert Bourla, the top five highest paid CEOs made a combined $157.8 million in 2025.
Partners Summit Therapeutics and Akeso are expected to steal the show at the American Society of Clinical Oncology’s annual conference with data from their potential Keytruda rival, alongside Revolution Medicine’s groundbreaking pancreatic cancer candidate and other assets that could reshape patient care.
The tragic tale of TIGIT is well known. However, RIPK1, myc, STING and alpha-synuclein have also left a trail of failed clinical trials, canceled partnerships and sunk investments in their wake.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
The Department of Health and Human Services is spinning its wheels, unable to establish steady leadership at three major divisions—the CDC and the FDA’s two primary review units.
THE LATEST
Before next-generation metabolomics becomes mainstream, the medical establishment needs to expand its mindset around cancer and translate this understanding into the clinic.
From artificial intelligence breakthroughs to at-home genetic testing, here are some ways COVID-19 has changed the biopharma industry and what we may see in the near future.
Court documents outline J&J’s involvement in a dermatology experiment 50 years ago on incarcerated individuals, most of whom were African American.
The single-shot chikungunya vaccine was shown to be safe and effective against mosquito-transmitted chikungunya disease in a published analysis of Phase III results.
From research to sales and marketing, the pharma industry has a wide range of employment opportunities to accommodate those looking for a chance to work in the field.
Voyager has partnered with Novartis for the latter to use the gene therapy company’s capsid discovery platform to create new treatments for three undisclosed CNS targets.
Potential outbreaks in Ukraine, genetic variants cause worsened symptoms, new long-term effects discovered and Florida political representatives advise against vaccines for kids.
Bristol Myers Squibb’s moneymaker cancer drug Revlimid has finally found a competitor in Israel-based Teva Pharmaceuticals’ generic version, lenalidomide.
Sanofi will more than $1 billion to build out its mRNA facilities and programs over the next several years. The site is expected to become operational in 2025.
Currently, women with breast and ovarian cancers have limited treatment options. Anixa Biosciences, ImmunoGen and IMV are working to change that.